Status:
COMPLETED
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
Lead Sponsor:
Peplin
Conditions:
Actinic Keratosis
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed to follow up patients, who have participated in the PEP005-028 study and observed complete clearance of their Actinic Keratosis (AK) lesions, over a 12 month period to assess bo...
Eligibility Criteria
Inclusion
- Inclusion
- Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures
- Patient achieved complete clearance of AK lesions (lesion count of 0) in the selected treatment area at the Day 57 visit in the following Peplin AK clinical Study: PEP005-028
- Exclusion
- Concurrent participation in another research study which would involve the selected treatment area (except for any post-study follow-up visits for previous Peplin AK study)
- Early termination from study PEP005-028
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00989313
Start Date
September 1 2009
End Date
October 1 2010
Last Update
March 26 2015
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Burke Pharmaceutical Research
Hot Springs, Arizona, United States, 71913
2
Skin Surgery Medical Group Inc.
San Diego, California, United States, 92117
3
Atlanta Dermatology, Vein & Research Center, LLC
Alpharetta, Georgia, United States, 30022
4
Altman Dermatology Associates
Arlington Heights, Illinois, United States, 60005